Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMEUR-IVL: Phase II R-CHOP plus high-dose methotrexate for untreated intravascular large B-cell lymphoma
jRCTs041180165Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and 1 more in intravascular large B-cell lymphoma (IVLBCL), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 2-year progression-free survival rate. Started Oct 2011; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
intravascular large B-cell lymphoma (IVLBCL)
Beyond the preview
Go deeper on jRCTs041180165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180165.